<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00782821</url>
  </required_header>
  <id_info>
    <org_study_id>X05274</org_study_id>
    <nct_id>NCT00782821</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients</brief_title>
  <official_title>Targeted Therapy for High Immunologic Risk Renal Transplant Recipients: A Prospective, Randomized, Open-Label Pilot Study of B-Cell Depleting Therapy in Combination With Anti-Thymocyte Globulin [Rabbit] (Thymoglobulin®, Genzyme), Tacrolimus (Prograf®, Astellas), Mycophenolate Mofetil (CellCept®, Roche) and Corticosteroid Minimization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out the effects of adding B lymphocyte
      modulating agents in patients at risk for rejection receiving an anti-rejection
      (immunosuppressive) regimen of Thymoglobulin® induction with Prograf®, Cellcept® and
      corticosteroid therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Optimal induction regimens for patients at high risk for antibody and/or cell-mediated
      rejection have not been established. This pilot, prospective, randomized study evaluated
      addition of B cell/plasma cell-targeting agents to T cell-based induction with rabbit
      antithymocyte globulin (rATG) in high immunologic risk renal transplant recipients. Patients
      were randomized to induction with rATG, rATGþrituximab, rATGþbortezomib or
      rATGþrituximabþbortezomib.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Acute Rejection (Banff '97) or Antibody Mediated Rejection</measure>
    <time_frame>6 months</time_frame>
    <description>Antibody mediated rejection demonstrated to be due to, atleast in part, to anti-donor antibody at 6 months by Banff 97' criteria.
Acute rejection IA - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of moderate tubulitis (&gt;4 mononuclear cells/tubular cross section or group of 10 tubular cells).
IB - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of severe tubulitis (&gt;10 mononuclear cells/tubular cross section or group of 10 tubular cells) IIA - cases with mild to moderate intimal arteritis (v1) IIB - cases with server intimal arteritis comprising &gt;25% of the luminal area (v2) III - case with transmural arteritis and/or arterial fibrinoid change and necrosis of medical smooth muscle cells (v3 with accompanying lymphoctic inflammation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody-mediated Rejection by Banff '97 Criteria (Updated 2005)</measure>
    <time_frame>6 months</time_frame>
    <description>Antibody mediated rejection demonstrated to be due to, atleast in part, to anti-donor antibody at 6 months by Banff 97' criteria. Rejection due, at least in part, to documented anti-donor antibody ('suspicious for' if antibody not demonstrated); may coincide with categories 3, 4 and 5.
Grade I. ATN-like - C4d+, minimal inflammation Grade II. Capillary- margination and/or thromboses, C4d+ Grade III. Arterial - v3, C4d+</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Cellular Rejection by Banff '97 Criteria (Updated 2005)</measure>
    <time_frame>6 months</time_frame>
    <description>Acute cellular rejection IA - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of moderate tubulitis (&gt;4 mononuclear cells/tubular cross section or group of 10 tubular cells).
IB - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of severe tubulitis (&gt;10 mononuclear cells/tubular cross section or group of 10 tubular cells) IIA - cases with mild to moderate intimal arteritis (v1) IIB - cases with server intimal arteritis comprising &gt;25% of the luminal area (v2) III - case with transmural arteritis and/or arterial fibrinoid change and necrosis of medical smooth muscle cells (v3 with accompanying lymphoctic inflammation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Survival at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Patient was still alive 12 months post study enrollment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Allograft Survival at 12 Months</measure>
    <time_frame>12 months</time_frame>
    <description>Patient's allograft was still functioning at 12 months post study enrollment</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Rabbit Antithymocyte Globulin (rATG)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rabbit Antithymocyte Globulin (rATG) 1.5mg/kg per dose x 6 doses rATG was administered on post-op day 0, 2, 4, 6, 8 and 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RATG/Rituxan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rabbit Antithymocyte Globulin (rATG)/Rituxan 1.5mg/kg per dose x 5 doses of rATG. 375mg/m2 x 1 dose of rituxan. rATG was administered on post-op day 0, 2, 4, 6 and 8. Rituxan was given on post-op day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RATG/Velcade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rabbit Antithymocyte Globulin (rATG) /Velcade 1.5mg/kg per dose x 5 doses of rATG. 1.3mg/m2 per dose x 4 doses of velcade. rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RATG/Rituxan/Velcade</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rabbit Antithymocyte Globulin (RATG) / Rituxan / Velcade 1.5mg/kg per dose x 4 doses of rATG. 200mg/m2 for 1 dose of rituxan. 1.3mg/m2 per dose x 4 doses of velcade.
rATG was administered on post-op day 0, 2, 4, and 6. Velcade was administered on post-op day 0, 3, 7 and 10. Rituxan was given on post-op day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit Antithymocyte Globulin</intervention_name>
    <description>rATG will be given 1.5mg/kg intravenous (IV) per dose.</description>
    <arm_group_label>Rabbit Antithymocyte Globulin (rATG)</arm_group_label>
    <arm_group_label>RATG/Rituxan</arm_group_label>
    <arm_group_label>RATG/Velcade</arm_group_label>
    <arm_group_label>RATG/Rituxan/Velcade</arm_group_label>
    <other_name>Thymoglobulin</other_name>
    <other_name>rATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velcade</intervention_name>
    <description>Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.</description>
    <arm_group_label>RATG/Velcade</arm_group_label>
    <arm_group_label>RATG/Rituxan/Velcade</arm_group_label>
    <other_name>bortezomib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituxan</intervention_name>
    <description>Given via IV per group assignment.</description>
    <arm_group_label>RATG/Rituxan</arm_group_label>
    <arm_group_label>RATG/Rituxan/Velcade</arm_group_label>
    <other_name>Rituximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Each patient must meet all of the following inclusion criteria to be enrolled in the study:

          -  Voluntary written informed consent before performance of any study-related procedure
             not part of normal medical care, with the understanding that consent may be withdrawn
             by the subject at any time without prejudice to future medical care.

          -  Patient is between the 18 and 65 years of age, inclusive.

          -  Patient is considered high risk for acute rejection based on any one of the following:

               -  Patient has a current Cytotoxic PRA≥ 20% or a peak Cytotoxic PRA ≥50%

               -  Patient has a T or B-cell positive crossmatch (by flow cytometry) with confirmed
                  donor-specific antibodies on solid-phase assay.

               -  Historical positive serologic or cytotoxic crossmatch or DSA to donor

               -  Prior allograft loss with a history of more than one acute rejection episode.

          -  Female subject is either postmenopausal for at least 1 year prior to initiation of
             study treatment, is surgically sterilized, or if of childbearing potential, agrees to
             practice 2 effective methods of contraception from the time of signing the informed
             consent form through 30 days after the last dose of bortezomib, or agrees to
             completely abstain from heterosexual intercourse. Women of childbearing potential must
             have a negative serum pregnancy test within the last 48 hours prior to receiving study
             medication.

          -  Male subjects, even if surgically sterilized (i.e. status post-vasectomy) must agree
             to 1 of the following: practice effective barrier contraception during the entire
             study treatment period and through a minimum of 30 days after the last dose of study
             drug, or completely abstain from heterosexual intercourse.

          -  Patient must have no known contraindications to treatment with bortezomib, rituximab,
             or thymoglobulin.

        Exclusion Criteria

          -  Patients that have previously received or are receiving an organ transplant other than
             kidney.

          -  Patient who lost a previous allograft due to recurrence of disease

          -  Patient is receiving a HLA identical living related kidney transplant

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             or polyclonal antibodies

          -  Patients with an absolute neutrophil count of &lt; 1,000/mm3 or platelet count &lt;
             100,000/mm3within 30 days of consent.

          -  Patient has Grade 2 peripheral neuropathy by CTCAE criteria within 14 days before
             enrollment.

          -  Myocardial infarction within 6 months prior to enrollment or has New York Heart
             Association (NYHA) Class III or IV heart failure (see section 9.3), uncontrolled
             angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence
             of acute ischemia or active conduction system abnormalities. Prior to study entry, any
             abnormality on ECG performed within 30 days of consent has to be documented by the
             investigator or the patient's transplant nephrologist as not medically relevant.

          -  Patients who are anti-HIV-positive, or HBsAg-positive or Anti-HCV positive on testing
             performed within one year of consent.

          -  Diagnosed or treated for malignancy within 3 years of enrollment, with the exception
             of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin,
             an in situ malignancy, or low-risk prostate cancer after curative therapy.

          -  Patients with current or recent severe systemic infections within the 2 weeks prior to
             initiation of study treatment.

          -  Receipt of a live vaccine within 4 weeks prior to initiation of study treatment.

          -  Use of other investigational drugs within 30 days or 5 half-lives prior to initiation
             of study treatment, whichever is longer

          -  Evidence of severe liver disease by medical history or physical exam with abnormal
             liver profile (aspartate aminotransferase [AST], alanine aminotransferase [ALT] or
             total bilirubin &gt; 1.5 times upper limit of normal [ULN]) on testing performed within
             30 days of consent.

          -  Pregnant or nursing (lactating) women and women who might become pregnant during the
             study. Female subject is pregnant or breast-feeding. Confirmation that the subject is
             not pregnant must be established by a negative serum -human chorionic gonadotropin
             pregnancy test result within the last 48 hours prior to receiving study medication.
             Pregnancy testing is not required for post-menopausal or surgically sterilized women.

          -  EBV serologic mismatch (i.e. EBV+ donor transplanted to EBV- recipient)

          -  CMV serologic mismatch (i.e. CMV+ donor transplanted to CMV- recipient)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>E. Steve Woodle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2008</study_first_submitted>
  <study_first_submitted_qc>October 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <results_first_submitted>October 20, 2015</results_first_submitted>
  <results_first_submitted_qc>December 14, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2016</results_first_posted>
  <last_update_submitted>December 14, 2015</last_update_submitted>
  <last_update_submitted_qc>December 14, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>E. Steve Woodle</investigator_full_name>
    <investigator_title>MD, FACS</investigator_title>
  </responsible_party>
  <keyword>Kidney</keyword>
  <keyword>Renal</keyword>
  <keyword>Rejection</keyword>
  <keyword>High risk</keyword>
  <keyword>Induction</keyword>
  <keyword>Immunology</keyword>
  <keyword>Transplantation</keyword>
  <keyword>B Cell</keyword>
  <keyword>Allograft</keyword>
  <keyword>Desensitization</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rabbit Antithymocyte Globulin (rATG)</title>
          <description>Thymoglobulin x 6 doses (1.5mg/kg IV).
Thymoglobulin is to be given on post operative days (POD) 0, 2, 4, 6 in all patients. Patients who receive a 5th dose will be administered a dose of Thymoglobulin on POD 8 and those who receive a 6th dose will be administered Thymoglobulin on POD 10. All groups will receive maintenance immunosuppression consisting of tacrolimus, mycophenolate mofetil, and corticosteroids (7 day corticosteroid taper to prednisone 5 mg daily).</description>
        </group>
        <group group_id="P2">
          <title>RATG/Rituxan</title>
          <description>Thymoglobulin x 5 doses (1.5mg/kg IV) + Rituximab 375mg/m2 IV
Thymoglobulin is to be given on post operative days (POD) 0, 2, 4, 6 in all patients. Patients who receive a 5th dose will be administered a dose of Thymoglobulin on POD 8 and those who receive a 6th dose will be administered Thymoglobulin on POD 10. All groups will receive maintenance immunosuppression consisting of tacrolimus, mycophenolate mofetil, and corticosteroids (7 day corticosteroid taper to prednisone 5 mg daily).</description>
        </group>
        <group group_id="P3">
          <title>RATG/Velcade</title>
          <description>Thymoglobulin x 5 doses (1.5mg/kg IV) + Velcade (1.3 mg/m2 IVP)
Thymoglobulin is to be given on post operative days (POD) 0, 2, 4, 6 in all patients. Patients who receive a 5th dose will be administered a dose of Thymoglobulin on POD 8 and those who receive a 6th dose will be administered Thymoglobulin on POD 10. All groups will receive maintenance immunosuppression consisting of tacrolimus, mycophenolate mofetil, and corticosteroids (7 day corticosteroid taper to prednisone 5 mg daily). Patients randomized to Arm C or D will receive 1.3 mg/m2 via IVP over 3-5 minutes on POD 0, 3, 7 and 10. The dose administered on POD 0 will be administered before pre-operatively before the pre-operative dose of methylprednisolone.</description>
        </group>
        <group group_id="P4">
          <title>RATG/Rituxan/Velcade</title>
          <description>Thymoglobulin x 4 doses (1.5mg/kg IV). + Rituximab 200mg/m2 IV + Bortezomib 1.3 mg/m2 IVP Thymoglobulin is to be given on post operative days (POD) 0, 2, 4, 6 in all patients. Patients who receive a 5th dose will be administered a dose of Thymoglobulin on POD 8 and those who receive a 6th dose will be administered Thymoglobulin on POD 10. All groups will receive maintenance immunosuppression consisting of tacrolimus, mycophenolate mofetil, and corticosteroids (7 day corticosteroid taper to prednisone 5 mg daily). Patients randomized to Arm C or D will receive 1.3 mg/m2 via IVP over 3-5 minutes on POD 0, 3, 7 and 10. The dose administered on POD 0 will be administered before pre-operatively before the pre-operative dose of methylprednisolone.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rabbit Antithymocyte Globulin (RATG)</title>
          <description>Thymoglobulin (RATG) x 6 doses (1.5mg/kg IV) Thymoglobulin is to be given on post operative days (POD) 0, 2, 4, 6 in all patients. Patients who receive a 5th dose will be administered a dose of Thymoglobulin on POD 8 and those who receive a 6th dose will be administered Thymoglobulin on POD 10. All groups will receive maintenance immunosuppression consisting of tacrolimus, mycophenolate mofetil, and corticosteroids (7 day corticosteroid taper to prednisone 5 mg daily).</description>
        </group>
        <group group_id="B2">
          <title>RATG/Rituxan</title>
          <description>Thymoglobulin (RATG) x 5 doses (1.5mg/kg IV)+ Rituximab 375mg/m2 IV
Thymoglobulin is to be given on post operative days (POD) 0, 2, 4, 6 in all patients. Patients who receive a 5th dose will be administered a dose of Thymoglobulin on POD 8 and those who receive a 6th dose will be administered Thymoglobulin on POD 10. All groups will receive maintenance immunosuppression consisting of tacrolimus, mycophenolate mofetil, and corticosteroids (7 day corticosteroid taper to prednisone 5 mg daily).</description>
        </group>
        <group group_id="B3">
          <title>RATG/Velcade</title>
          <description>Thymoglobulin (RATG) x 5 doses (1.5mg/kg IV) + Velcade (1.3 mg/m2 IVP)
Thymoglobulin is to be given on post operative days (POD) 0, 2, 4, 6 in all patients. Patients who receive a 5th dose will be administered a dose of Thymoglobulin on POD 8 and those who receive a 6th dose will be administered Thymoglobulin on POD 10. All groups will receive maintenance immunosuppression consisting of tacrolimus, mycophenolate mofetil, and corticosteroids (7 day corticosteroid taper to prednisone 5 mg daily).</description>
        </group>
        <group group_id="B4">
          <title>RATG/Rituxan/Velcade</title>
          <description>Thymoglobulin x 4 doses (1.5mg/kg IV)+ Rituximab 200mg/m2 IV + Velcade (1.3 mg/m2 IVP)
Thymoglobulin is to be given on post operative days (POD) 0, 2, 4, 6 in all patients. Patients who receive a 5th dose will be administered a dose of Thymoglobulin on POD 8 and those who receive a 6th dose will be administered Thymoglobulin on POD 10. All groups will receive maintenance immunosuppression consisting of tacrolimus, mycophenolate mofetil, and corticosteroids (7 day corticosteroid taper to prednisone 5 mg daily).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="10"/>
            <count group_id="B5" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" lower_limit="46.3" upper_limit="53.8"/>
                    <measurement group_id="B2" value="52.8" lower_limit="45.6" upper_limit="62.7"/>
                    <measurement group_id="B3" value="50.6" lower_limit="34.5" upper_limit="63.3"/>
                    <measurement group_id="B4" value="50.1" lower_limit="45.3" upper_limit="56.9"/>
                    <measurement group_id="B5" value="50.9" lower_limit="34.5" upper_limit="63.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-transplant diabetes mellitus</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dialysis pre-transplant</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Acute Rejection (Banff ’97) or Antibody Mediated Rejection</title>
        <description>Antibody mediated rejection demonstrated to be due to, atleast in part, to anti-donor antibody at 6 months by Banff 97' criteria.
Acute rejection IA - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of moderate tubulitis (&gt;4 mononuclear cells/tubular cross section or group of 10 tubular cells).
IB - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of severe tubulitis (&gt;10 mononuclear cells/tubular cross section or group of 10 tubular cells) IIA - cases with mild to moderate intimal arteritis (v1) IIB - cases with server intimal arteritis comprising &gt;25% of the luminal area (v2) III - case with transmural arteritis and/or arterial fibrinoid change and necrosis of medical smooth muscle cells (v3 with accompanying lymphoctic inflammation)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rabbit Antithymocyte Globulin (RATG)</title>
            <description>Thymoglobulin x 6 doses</description>
          </group>
          <group group_id="O2">
            <title>RATG/Rituxan</title>
            <description>Thymoglobulin x 5 doses + Rituximab 375mg/m2</description>
          </group>
          <group group_id="O3">
            <title>RATG/Velcade</title>
            <description>Thymoglobulin x 5 doses + Velcade</description>
          </group>
          <group group_id="O4">
            <title>RATG/Rituxan/Velcade</title>
            <description>Thymoglobulin x 4 doses + Rituximab 200mg/m2 + Velcade</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Acute Rejection (Banff ’97) or Antibody Mediated Rejection</title>
          <description>Antibody mediated rejection demonstrated to be due to, atleast in part, to anti-donor antibody at 6 months by Banff 97' criteria.
Acute rejection IA - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of moderate tubulitis (&gt;4 mononuclear cells/tubular cross section or group of 10 tubular cells).
IB - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of severe tubulitis (&gt;10 mononuclear cells/tubular cross section or group of 10 tubular cells) IIA - cases with mild to moderate intimal arteritis (v1) IIB - cases with server intimal arteritis comprising &gt;25% of the luminal area (v2) III - case with transmural arteritis and/or arterial fibrinoid change and necrosis of medical smooth muscle cells (v3 with accompanying lymphoctic inflammation)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Antibody-mediated Rejection by Banff '97 Criteria (Updated 2005)</title>
        <description>Antibody mediated rejection demonstrated to be due to, atleast in part, to anti-donor antibody at 6 months by Banff 97' criteria. Rejection due, at least in part, to documented anti-donor antibody (‘suspicious for’ if antibody not demonstrated); may coincide with categories 3, 4 and 5.
Grade I. ATN-like – C4d+, minimal inflammation Grade II. Capillary- margination and/or thromboses, C4d+ Grade III. Arterial – v3, C4d+</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rabbit Antithymocyte Globulin (RATG)</title>
            <description>Thymoglobulin x 6 doses</description>
          </group>
          <group group_id="O2">
            <title>RATG/Rituxan</title>
            <description>Thymoglobulin x 5 doses + Rituximab 375mg/m2</description>
          </group>
          <group group_id="O3">
            <title>RATG/Velcade</title>
            <description>Thymoglobulin x 5 doses + Velcade</description>
          </group>
          <group group_id="O4">
            <title>RATG/Rituxan/Velcade</title>
            <description>Thymoglobulin x 4 doses + Rituximab 200mg/m2 + Velcade</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody-mediated Rejection by Banff '97 Criteria (Updated 2005)</title>
          <description>Antibody mediated rejection demonstrated to be due to, atleast in part, to anti-donor antibody at 6 months by Banff 97' criteria. Rejection due, at least in part, to documented anti-donor antibody (‘suspicious for’ if antibody not demonstrated); may coincide with categories 3, 4 and 5.
Grade I. ATN-like – C4d+, minimal inflammation Grade II. Capillary- margination and/or thromboses, C4d+ Grade III. Arterial – v3, C4d+</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Cellular Rejection by Banff '97 Criteria (Updated 2005)</title>
        <description>Acute cellular rejection IA - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of moderate tubulitis (&gt;4 mononuclear cells/tubular cross section or group of 10 tubular cells).
IB - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of severe tubulitis (&gt;10 mononuclear cells/tubular cross section or group of 10 tubular cells) IIA - cases with mild to moderate intimal arteritis (v1) IIB - cases with server intimal arteritis comprising &gt;25% of the luminal area (v2) III - case with transmural arteritis and/or arterial fibrinoid change and necrosis of medical smooth muscle cells (v3 with accompanying lymphoctic inflammation)</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rabbit Antithymocyte Globulin (RATG)</title>
            <description>Thymoglobulin x 6 doses</description>
          </group>
          <group group_id="O2">
            <title>RATG/Rituxan</title>
            <description>Thymoglobulin x 5 doses + Rituximab 375mg/m2</description>
          </group>
          <group group_id="O3">
            <title>RATG/Velcade</title>
            <description>Thymoglobulin x 5 doses + Bortezomib</description>
          </group>
          <group group_id="O4">
            <title>RATG/Rituxan/Velcade</title>
            <description>Thymoglobulin x 4 doses + Rituximab 200mg/m2 + Bortezomib</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Cellular Rejection by Banff '97 Criteria (Updated 2005)</title>
          <description>Acute cellular rejection IA - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of moderate tubulitis (&gt;4 mononuclear cells/tubular cross section or group of 10 tubular cells).
IB - cases with significant interstitial infiltration (&gt;25% of parenchyma affected) and foci of severe tubulitis (&gt;10 mononuclear cells/tubular cross section or group of 10 tubular cells) IIA - cases with mild to moderate intimal arteritis (v1) IIB - cases with server intimal arteritis comprising &gt;25% of the luminal area (v2) III - case with transmural arteritis and/or arterial fibrinoid change and necrosis of medical smooth muscle cells (v3 with accompanying lymphoctic inflammation)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Survival at 12 Months</title>
        <description>Patient was still alive 12 months post study enrollment.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rabbit Antithymocyte Globulin (RATG)</title>
            <description>Thymoglobulin (RATG) x 6 doses (1.5mg/kg IV)</description>
          </group>
          <group group_id="O2">
            <title>RATG/Rituxan</title>
            <description>Thymoglobulin x 5 doses + Rituximab 375mg/m2</description>
          </group>
          <group group_id="O3">
            <title>RATG/Velcade</title>
            <description>Thymoglobulin x 5 doses + Velcade</description>
          </group>
          <group group_id="O4">
            <title>RATG/Rituxan/Velcade</title>
            <description>Thymoglobulin x 4 doses + Rituximab 200mg/m2 + Bortezomib</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Survival at 12 Months</title>
          <description>Patient was still alive 12 months post study enrollment.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Allograft Survival at 12 Months</title>
        <description>Patient's allograft was still functioning at 12 months post study enrollment</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rabbit Antithymocyte Globulin (RATG)</title>
            <description>Rabbit Antithymocyte Globulin (RATG)
Rabbit Antithymocyte Globulin (RATG): RATG</description>
          </group>
          <group group_id="O2">
            <title>RATG/Rituxan</title>
            <description>Rabbit Antithymocyte Globulin (RATG)/Rituxan
RATG/Rituxan: RATG/Rituxan
RATG/Rituxan/Velcade: Rabbit Antithymocyte Globulin (RATG)/ Rituxan/ Velcade</description>
          </group>
          <group group_id="O3">
            <title>RATG/Velcade</title>
            <description>Rabbit Antithymocyte Globulin (RATG) /Velcade
RATG/Rituxan/Velcade: Rabbit Antithymocyte Globulin (RATG)/ Rituxan/ Velcade</description>
          </group>
          <group group_id="O4">
            <title>RATG/Rituxan/Velcade</title>
            <description>Rabbit Antithymocyte Globulin (RATG) / Rituxan / Velcade
RATG/Velcade: RATG/Velcade</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Allograft Survival at 12 Months</title>
          <description>Patient's allograft was still functioning at 12 months post study enrollment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rabbit Antithymocyte Globulin (RATG)</title>
          <description>Rabbit Antithymocyte Globulin (RATG)
Rabbit Antithymocyte Globulin (RATG): RATG</description>
        </group>
        <group group_id="E2">
          <title>RATG/Rituxan</title>
          <description>Rabbit Antithymocyte Globulin (RATG)/Rituxan
RATG/Rituxan: RATG/Rituxan
RATG/Rituxan/Velcade: Rabbit Antithymocyte Globulin (RATG)/ Rituxan/ Velcade</description>
        </group>
        <group group_id="E3">
          <title>RATG/Velcade</title>
          <description>Rabbit Antithymocyte Globulin (RATG) /Velcade
RATG/Rituxan/Velcade: Rabbit Antithymocyte Globulin (RATG)/ Rituxan/ Velcade</description>
        </group>
        <group group_id="E4">
          <title>RATG/Rituxan/Velcade</title>
          <description>Rabbit Antithymocyte Globulin (RATG) / Rituxan / Velcade
RATG/Velcade: RATG/Velcade</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>CMV +/- Status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CMV Viremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CMV Invasive Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>EBV +/- Status</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>EBV Viremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>EBV-related disease / PTLD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>BKV Viremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>BKV Nephropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Other Infections</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CTCAE Grade 1 Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CTCAE Grade 2 Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CTCAE Grade 3 Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CTCAE Grade 1 Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CTCAE Grade 2 Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>CTCAE Grade 3 Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>E. Steve Woodle, MD</name_or_title>
      <organization>University of Cincinnati</organization>
      <phone>513-558-6001</phone>
      <email>woodlees@ucmail.uc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

